中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

20 records (took 0.023 seconds)

    METHODS OF USING PD-L1 EXPRESSION IN TREATMENT DECISIONS FOR CANCER THERAPY
    1.
    发明申请
    METHODS OF USING PD-L1 EXPRESSION IN TREATMENT DECISIONS FOR CANCER THERAPY 审中-公开
    使用PD-L1表达治疗癌症治疗的方法

    公开(公告)号：WO2017181073A1

    公开(公告)日：2017-10-19

    申请号：PCT/US2017/027714

    申请日：2017-04-14

    Applicant: CREATV MICROTECH, INC.

    Inventor： ADAMS, Daniel ,  TANG, Cha-Mei

    IPC: C07K16/28 ,  C12N5/00 ,  G01N33/574

    Abstract: Methods of using detection of PD-L1 expression by circulating cancer cells in the screening, monitoring, treatment and diagnosis of cancer in subjects are disclosed. The methods are based on assaying one or more of circulating tumor cells (CTCs), epithelial to mesenchymal transition CTCs (EMTCTCs), cancer associated macrophage-like cells (CAMLs), and cancer associated vascular endothelial cells (CAVEs) isolated from a subject having cancer for PD-L1 expression.

    Abstract translation: 在受试者中筛选，监测，治疗和诊断癌症时，公开了通过使癌细胞循环检测PD-L1表达的方法。 该方法基于分析自患有以下疾病的受试者分离的循环肿瘤细胞（CTC），上皮细胞间质转化CTC（EMTCTC），癌症相关巨噬细胞样细胞（CAML）和癌症相关血管内皮细胞（CAVE）中的一种或多种： 癌症为PD-L1表达。

    URINE PRESERVATIVE REAGENT FOR MICROFILTRATION
    2.
    发明申请
    URINE PRESERVATIVE REAGENT FOR MICROFILTRATION 审中-公开
    尿液保护试剂

    公开(公告)号：WO2014151437A1

    公开(公告)日：2014-09-25

    申请号：PCT/US2014/025728

    申请日：2014-03-13

    Applicant: CREATV MICROTECH, INC.

    Inventor： ZHU, Peixuan ,  ADAMS, Daniel ,  TANG, Cha-Mei

    IPC: A01N1/02 ,  G01N33/48

    CPC classification number: A01N1/021 ,  A01N1/0215 ,  G01N33/493 ,  G01N33/574

    Abstract: A preservative reagent for urine is disclosed that increases the stability of cells, such as tumor cells, in urine for a period of several weeks. The preservative reagent comprises polyethylene glycol (PEG), ethanol, paraformaldehyde (PFA), and ethylenediaminetetraacetic acid (EDTA), and optionally pH stabilizing reagents.

    Abstract translation: 公开了用于尿液的防腐剂，其在尿液中增加细胞（例如肿瘤细胞）的稳定性，持续数周。 防腐剂包括聚乙二醇（PEG），乙醇，多聚甲醛（PFA）和乙二胺四乙酸（EDTA），以及任选的pH稳定试剂。

    USE OF CIRCULATING TUMOR CELL MITOTIC INDEX IN CANCER STRATIFICATION AND DIAGNOSTICS
    9.
    发明申请
    USE OF CIRCULATING TUMOR CELL MITOTIC INDEX IN CANCER STRATIFICATION AND DIAGNOSTICS 审中-公开
    循环肿瘤细胞毒性指数在癌症分期和诊断中的应用

    公开(公告)号：WO2016191532A1

    公开(公告)日：2016-12-01

    申请号：PCT/US2016/034261

    申请日：2016-05-26

    Applicant: CREATV MICROTECH INC.

    Inventor： ADAMS, Daniel ,  TANG, Cha-Mei

    IPC: G01N33/50 ,  G01N33/574

    CPC classification number: G01N33/574 ,  G01N33/5005 ,  G01N33/5091 ,  G01N33/57415 ,  G01N33/57423 ,  G01N33/5743 ,  G01N33/57434 ,  G01N33/57438 ,  G01N33/57446 ,  G01N2800/52 ,  G01N2800/56 ,  G01N2800/7028

    Abstract: Circulating tumor cells (CTCs) are associated with metastasis of malignant solid tumors in a patient. Presented here is evidence that CTCs exhibit cell cycle phase variability and that there is a strong correlation between the number of CTCs in a mitotic cell cycle phase and the prospects for long term survival of the subject from which the cells were obtained. Also presented herein are methods of determining the mitotic cell cycle phase of CTCs from a patient having cancer and using the information in grading malignant solid tumors and predicting the likelihood of survival of the patient.

    Abstract translation: 循环肿瘤细胞（CTC）与患者恶性实体瘤的转移相关。 这里提出的证据表明，CTC表现出细胞周期相位变异性，并且在有丝分裂细胞周期阶段中CTC的数量与从其获得细胞的受试者的长期存活的前景之间存在很强的相关性。 本文还介绍了确定来自患有癌症的患者的CTC的有丝分裂细胞周期阶段并使用分级恶性实体瘤的信息并预测患者存活的可能性的方法。

Patent Agency Ranking